Abstract
Camrelizumab (AiRuiKa (TM)), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditi......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
